Thursday, 13 November 2025
  
Login

Australia's most trusted
source of pharma news

Thursday, 13 November 2025
News

MSD pips AZ in first-to-market race

Posted 13 November 2026 AM 

MSD is winning the race to bring the first oral PCSK9 inhibitor to market, after its daily pill enlicitide decanoate produced similar results to existing injectables in two Phase 3 trials.

Both MSD and AstraZeneca are developing PCSK9 inhibitor once-daily pills. Sales of the three approved injectable PCSK9 inhibitors - Amgen’s Repatha, Sanofi’s Praluent and Novartis’s Leqvio - are growing but have failed to meet expectations.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (16)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (4)

Other (14)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.